A Case of Pseudoprogression During Atezolizumab Therapy
in Lung Adenocarcinoma.
10.3779/j.issn.1009-3419.2019.06.10
- Author:
Xue WANG
1
;
Yi ZHAO
1
;
Zhiwei CHEN
1
Author Information
1. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China.
- Publication Type:Case Reports
- Keywords:
Atezolizumab;
Immunotherapy;
NSCLC;
PD-L1;
Pseudoprogression
- MeSH:
Antibodies, Monoclonal;
administration & dosage;
Antineoplastic Agents, Immunological;
administration & dosage;
Carcinoma, Non-Small-Cell Lung;
diagnostic imaging;
drug therapy;
Humans;
Immunotherapy;
Lung Neoplasms;
diagnostic imaging;
drug therapy;
Male;
Middle Aged
- From:
Chinese Journal of Lung Cancer
2019;22(6):389-394
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common cause of cancer-related death worldwide. There are two classes of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC represents approximately 85% of all lung cancer cases. Immune checkpoint inhibitors (ICIPs) are a class of inhibitors of programmed death-1 and programmed death-ligand 1. Preclinical studies have shown that ICIPs have shown good clinical efficacy and durable response in diverse cancers. Among them, atezolizumab (MPDL3280), an anti-PD-L1 monoclonal antibody, is being investigated as a potential therapy against solid tumors and hematologic malignancies in humans. Pseudoprogression is reported as one of the unique phenomena with immune therapeutic agents. Here we report case of a person with advanced NSCLC who developed pseudoprogression after receiving immunotherapy. We hope this case could help clinicians to make appropriate decision when assessing therapeutic effects of immunotherapy.
.
